<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250051</url>
  </required_header>
  <id_info>
    <org_study_id>NU 19H05</org_study_id>
    <secondary_id>STU00210558</secondary_id>
    <secondary_id>NU 19H05</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NCI-2019-08390</secondary_id>
    <nct_id>NCT04250051</nct_id>
  </id_info>
  <brief_title>Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agios Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ivosidenib when given together
      with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that
      has come back (relapsed) or does not respond to treatment (refractory). Ivosidenib may stop
      the growth of cancer cells by blocking the IDH1 mutation and some of the enzymes needed for
      cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and
      filgrastim, work in different ways to stop the growth of cancer cells, either by killing the
      cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib
      with combination chemotherapy may work better in treating patients with acute myeloid
      leukemia compared to chemotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To determine the maximum tolerated dose (MTD) of ivosidenib in combination with
      fludarabine, cytarabine, plus granulocyte-colony stimulating factor (G-CSF) (FLAG)
      chemotherapy.

      SECONDARY OBJECTIVES:

      I. To evaluate the safety profile of ivosidenib in combination with FLAG chemotherapy.

      II. To determine the rate of complete remission (CR + complete remission with incomplete
      hematological recovery [CRi] + complete remission with incomplete platelet recovery [CRp])
      with ivosidenib in combination with FLAG chemotherapy.

      III. To evaluate the 1 year progression free survival. IV. To evaluate the 1 year overall
      survival. V. To assess the number of patients that receive allogeneic stem cell transplant
      after ivosidenib in combination with FLAG chemotherapy.

      EXPLORATORY OBJECTIVES:

      I. To assess for minimal residual disease negativity by polymerase chain reaction (PCR) for
      IDH1 mutations after treatment with ivosidenib in combination with FLAG chemotherapy.

      II. To assess for minimal residual disease negativity by PCR for IDH1 mutations after 3
      cycles of maintenance therapy.

      OUTLINE:

      INDUCTION: Patients receive filgrastim subcutaneously (SC) once daily (QD) on days 0-6,
      fludarabine phosphate intravenously (IV) QD over 30 minutes on days 1-5, cytarabine IV QD
      over 4 hours on days 1-5, and ivosidenib orally (PO) QD on days 7-28. Treatment continues for
      28 days in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD
      over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD
      on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease
      progression or unacceptable toxicity.

      MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days
      for up to 26 cycles in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every month
      for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to day 42 of the first treatment cycle</time_frame>
    <description>Will be assessed for a DLT per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Will be assessed by the CTCAE version 5.0. Toxicity profiles will be summarized for toxicities of any grade, with rates of &gt;= grade 3 toxicities also analyzed separately. Adverse events rates will be summarized and accompanied by 95% exact binomial confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complete remission (CR + complete remission with incomplete hematological recovery [CRi] + complete remission with incomplete platelet recovery [CRp])</measure>
    <time_frame>After induction on day 28 or upon count recovery, up to 1 year</time_frame>
    <description>Patients that complete the induction cycle will be eligible for assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that receive hematopoietic stem cell transplant after induction treatment</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Patients that complete the induction cycle will be eligible for assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Myelodysplastic Syndrome</condition>
  <condition>Recurrent Myeloproliferative Neoplasm</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivosidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>AG-120</other_name>
    <other_name>Tibsovo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have relapsed/refractory primary (ie, de novo) or secondary (progression
             of myelodysplastic syndrome [MDS] or myeloproliferative neoplasms [MPN], or
             therapy-related) acute myeloid leukemia (AML) according to the World Health
             Organization (WHO) classification with &gt;= 5% leukemic blasts in the bone marrow

          -  Patients may have received prior therapies and there are no limits on number of
             therapies

               -  Note: There is a requirement of 7 day washout from prior therapy or 5 half-lives,
                  whichever is shorter

          -  Patient must have documentation of an IDH1 R132 mutation obtained prior to
             registration. IDH mutational status will be assessed locally

          -  Patients must understand and voluntarily sign an informed consent form (ICF) prior to
             any study-related assessments/procedures being conducted

          -  Patient is willing and able to adhere to the study visit schedule and other protocol
             requirements

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or
             2

          -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT)
             and alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             upper limit of normal (ULN), unless considered due to leukemic organ involvement
             (within 28 days prior to registration)

          -  Serum total bilirubin &lt; 1.5 x ULN (within 28 days prior to registration)

               -  Higher levels are acceptable if these can be attributed to ineffective
                  erythropoiesis, =&lt; 3 times the upper limit of normal for Gilbert's syndrome (eg,
                  a gene mutation in UGT1A1), or leukemic organ involvement

          -  Serum creatinine or creatinine clearance &lt; 2 x ULN or &gt;= 30 mL/min based on the
             Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR) (within
             28 days prior to registration)

          -  Patients must agree to serial bone marrow aspirate/biopsies

          -  Females of childbearing potential (FOCBP) may participate, providing they meet the
             following conditions: Agree to practice true abstinence from sexual intercourse or to
             use two highly effective contraceptive methods, of which one must be a barrier method
             (eg, combined [containing estrogen and progestogen] or progestogen only associated
             with inhibition of ovulation, oral, injectable, intravaginal, patch, or implantable
             hormonal contraceptive; bilateral tubal occlusion; intra-uterine device; intrauterine
             hormone-releasing system; or male partner sterilization [note that a vasectomized
             partner is a highly effective birth control method provided that partner is the sole
             sexual partner of the FOCBP trial participant and that a vasectomized partner has
             received medical assessment of the surgical success]) at screening and throughout the
             study, and for at least 4 months following the last study treatment.

               -  NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a
                  tubal ligation, or remaining celibate by choice) who meets the following
                  criteria:

                    -  Has not undergone a hysterectomy or bilateral oophorectomy

                    -  Has had menses at any time in the preceding 12 consecutive months (and
                       therefore has not been naturally postmenopausal for &gt; 12 months)

          -  Female patients must have a negative serum beta-subunit of human chorionic
             gonadotropin (beta-hCG) pregnancy test (sensitivity of at least 25 mIU/mL) 28 days
             prior to registration on study and have a negative serum or urine (investigator's
             discretion under local regulations) Î²-hCG pregnancy test (sensitivity of at least 25
             mIU/mL) within 72 hours prior to the start of study treatment in the Treatment Period.

               -  Note: the screening serum pregnancy test can be used as the test prior to the
                  start of study treatment in the Treatment Period if it is performed within the
                  72-hour time frame)

          -  Male patients must agree to practice true abstinence from sexual intercourse or agree
             to the use of highly effective contraceptive methods (as described above) with
             non-pregnant female partners of child bearing potential at screening and throughout
             the course of the study and should avoid conception with their partners during the
             course of the study and for at least 4 months following the last study treatment.

               -  Furthermore, the male subject must agree to use a condom while treated with
                  ivosidenib and for at least 4 months following the last ivosidenib dose

        Exclusion Criteria:

          -  Patients who are suspected or proven to have acute promyelocytic leukemia based on
             morphology, immunophenotype, molecular assay, or karyotype are not eligible

          -  Patients who have had prior therapy with ivosidenib are not eligible.

               -  Note: prior treatment with other IDH inhibitors are allowed

          -  Patients who have immediate life-threatening, uncontrolled medical problem that would
             prevent treatment on a clinical trial per investigator's discretion are not eligible

          -  Patients who have significant active cardiac disease within 28 days prior to study
             registration, including New York Heart Association (NYHA) class III or IV congestive
             heart failure; acute coronary syndrome (ACS); and/or stroke; or left ventricular
             ejection fraction (LVEF) &lt; 40% by echocardiogram (ECHO) or multi-gated acquisition
             (MUGA) scan obtained within 28 days prior to study registration are not eligible

          -  Patients who have prior history of malignancy, other than MDS, MPN, or AML are not
             eligible unless the subject has been free of the disease for &gt;= 1 year prior to the
             start of study treatment. However, subjects with the following history/concurrent
             conditions are allowed:

               -  Basal or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast Incidental histologic finding of prostate cancer
                  (T1a or T1b using the tumor, node, metastasis clinical staging system)

          -  Patients who are known to have short-gut syndrome, gastroparesis, or other conditions
             that limit the ingestion or gastrointestinal absorption of drugs administered orally
             are not eligible

          -  Patients who are taking the following sensitive CYP substrate medications that have a
             narrow therapeutic range are excluded from the study unless the subject can be
             transferred to other medications at least 5 half-lives or 14 days whichever is shorter
             prior to the start of study treatment: phenytoin (CYP2C9), S-mephenytoin (CYP2C19),
             thioridazine (CYP2D6), theophylline, tizanidine (CYP1A2), CYP2C8, CYP3A4/5, and CYP2B6

          -  Patients who are known to be taking strong CYP3A4 inducers or sensitive CYP3A4
             substrate medications that have a narrow therapeutic window are not eligible, unless
             they can be transferred to other medications within &gt;= 5 half-lives prior to dosing or
             unless the medications can be properly monitored during the study

          -  Patients with an active uncontrolled systemic fungal, bacterial, or viral infection
             (defined as ongoing signs/symptoms related to the infection without improvement
             despite appropriate antibiotics, antiviral therapy, and/or other treatment) are not
             eligible

          -  Patients who have known or suspected hypersensitivity to any of the components of
             study therapy are not eligible

          -  Patient who has corrected QT (QTc) interval (Frederica's correction [QTcF]) &gt;= 480 ms)
             at screening unless attributable to bundle branch block or pacemaker are not eligible.
             If prolonged QTc is attributed to medications the patient must be transferred to other
             medications and QTc corrected to selection parameters prior to enrollment

          -  Female patients who are pregnant or nursing are not eligible

          -  Patients who have any significant medical condition, laboratory abnormality, or
             psychiatric illness that the treating physician believes would prevent the subject
             from participating in the study are not eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shira N Dinner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>(312)695-1301</phone>
    <email>cancertrials@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shira N. Dinner, M.D.</last_name>
      <phone>312-695-6180</phone>
      <email>Shira.dinner@nm.org</email>
    </contact>
    <investigator>
      <last_name>Shira N. Dinner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Ivosidenib</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

